Vogl Thomas J, Freichel Jason, Gruber-Rouh Tatjana, Nour-Eldin Nour-Eldin Abdelrehim, Bechstein Wolf-Otto, Zeuzem Stefan, Naguib Nagy N N, Stefenelli Ulrich, Adwan Hamzah
Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.
Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Cairo University, Cairo 12613, Egypt.
Cancers (Basel). 2024 Apr 30;16(9):1756. doi: 10.3390/cancers16091756.
The aim of this study was to analyze the long-term results of different locoregional treatments for colorectal cancer liver metastases (CRLM), including transarterial chemoembolization (TACE), laser-induced thermotherapy (LITT) and microwave ablation (MWA). A total of 2140 patients with CRLM treated at our department between 1993 and 2020 were included in this retrospective study. The patients were divided into the following groups: LITT (573 patients; median age: 62 years), TACE + LITT (346 patients; median age: 62 years), MWA (67 patients; median age: 59 years), TACE + MWA (152 patients; median age: 65 years), and TACE (1002 patients; median age: 62 years). Median survival was 1.9 years in the LITT group and 1.7 years in the TACE + LITT group. The median survival times in the MWA group and TACE + MWA group were 3.1 years and 2.1 years, respectively. The median survival in the TACE group was 0.8 years. The 1-, 3-, and 5-year survival rates were 77%, 27%, and 9% in the LITT group and 74%, 18%, and 5% in the TACE + LITT group, respectively. The corresponding survival rates were 80%, 55%, and 33% in the MWA group, 74%, 36%, and 20% in the TACE + MWA group and 37%, 3%, and 0% in the TACE group, respectively. The long-term results of this study demonstrate the efficacy of locoregional treatments in treating patients with CRLM. The longest survival was found in the MWA group, followed by the combination therapy of TACE and MWA.
本研究的目的是分析不同局部区域治疗方法对结直肠癌肝转移（CRLM）的长期疗效，包括经动脉化疗栓塞术（TACE）、激光诱导热疗（LITT）和微波消融术（MWA）。本回顾性研究纳入了1993年至2020年期间在我科接受治疗的2140例CRLM患者。患者被分为以下几组：LITT组（573例患者；中位年龄：62岁）、TACE + LITT组（346例患者；中位年龄：62岁）、MWA组（67例患者；中位年龄：59岁）、TACE + MWA组（152例患者；中位年龄：65岁）和TACE组（1002例患者；中位年龄：62岁）。LITT组的中位生存期为1.9年，TACE + LITT组为1.7年。MWA组和TACE + MWA组的中位生存期分别为3.1年和2.1年。TACE组的中位生存期为0.8年。LITT组的1年、3年和5年生存率分别为77%、27%和9%，TACE + LITT组分别为74%、18%和5%。MWA组相应的生存率分别为80%、55%和33%，TACE + MWA组分别为74%、36%和20%，TACE组分别为37%、3%和0%。本研究的长期结果表明局部区域治疗对CRLM患者有效。MWA组的生存期最长，其次是TACE与MWA的联合治疗。
